8-K: Current report filing
Published on January 11, 2007
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
Current
Report Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of
Report (Date of Earliest Event Reported): January 5, 2007
LIXTE
BIOTECHNOLOGY HOLDINGS, INC.
(Exact
Name of Registrant as Specified in its Charter)
Delaware
(State
or
Other Jurisdiction of Incorporation)
|
000-51476
|
|
20-2903526
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer Identification No.)
|
|
248
Route 25A, No. 2, East Setauket, New York
|
|
11733
|
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
631-942-7959
(Registrant’s
Telephone Number, Including Area Code)
SRKP
7,
INC.
1900
Avenue of the Stars, Los Angeles, CA 90067
(Former
Name or Former Address, if Changed Since Last Report)
.
|
Item
1.01
|
Entry
into a Material Agreement
|
On
January 5, 2007 (the “Effective Date”), Lixte Biotechnology, Inc. (“Lixte”), the
wholly owned subsidiary of Lixte Biotechnology Holdings, Inc. (the “Company”)
entered into a Services Agreement with The Free State of Bavaria (Germany)
represented by the University of Regensburg (the “University”) pursuant to which
Lixte retained the University to provide to it certain samples of primary cancer
tissue and related biological fluids to be obtained from patients afflicted
with
specified types of cancer. The University will also provide certain information
relating to such patients. Lixte will pay the University 72,000 Euros in two
installments of 36,000 Euros, the first installment to be paid within sixty
days
of the Effective Date and the second installment to be paid within sixty days
of
the earlier of (i) the first anniversary of the Effective Date or (ii) the
University’s fulfillment of certain obligations relating to the delivery of
materials.
| Item 8.01 |
Other
Events
|
On
January 11, 2007, the Company issued a press release announcing the entering
into of the Services Agreement referred to in Item 1.01.
| Item 9. |
Financial
Statements and Exhibits
|
(c) Exhibits
| Exhibit 10.1 |
Services
Agreement between Lixte Biotechnology, Inc. and Freestate of Bavaria
represented by University of
Regensburg.
|
| Exhibit 99.1 |
Press
Release
|
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
LIXTE
BIOTECHNOLOGY HOLDINGS, INC.
|
||
| |
|
|
|
Date:
January 11, 2007
|
By: | /s/ John S. Kovach |
|
John
S. Kovach, Chairman of the Board and Chief Executive Officer (principal
executive officer)
|
||
3